Reneo Pharmaceuticals Inc - Class A
Research Reneo Pharmaceuticals Inc - Class A (OKUR) on Bullrun: market cap USD 98.00M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOKUR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 98.00M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 15.35M
- Free cash flow-USD 10.36M
Valuation Snapshot
latest market cap is USD 98.00M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 59.52M | -USD 51.87M | n/a | -4.4 | USD 59.05M | USD 549.00K | USD 56.18M |
| FY2024 | USD 0 | -USD 52.67M | -USD 51.17M | n/a | -15.28 | USD 110.76M | USD 1.09M | USD 103.83M |
| FY2023 | USD 0 | -USD 35.31M | -USD 34.79M | n/a | -124.41 | USD 29.88M | USD 674.00K | -USD 101.84M |
| FY2022 | USD 0 | -USD 51.96M | -USD 47.71M | n/a | -2.12 | USD 19.93M | USD 637.00K | -USD 54.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 98.00M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 39.65M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 114.79M | n/a | n/a | n/a |
About Reneo Pharmaceuticals Inc - Class A
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Reneo Pharmaceuticals Inc - Class A's market cap?
Reneo Pharmaceuticals Inc - Class A's market capitalization is USD 98.00M.
What does Reneo Pharmaceuticals Inc - Class A do?
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.